Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma

Ryu Tiger, Y. K., Jain, S., Barta, S. K., Tolu, S., Estrella, B., Sawas, A., Lue, J. K., Francescone, M. M., Pro, B., & Amengual, J. E. (2024). Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leukemia & Lymphoma, 65(6), 736–745. https://doi.org/10.1080/10428194.2024.2329996
Authors:
Yun Kyoung Ryu Tiger
Salvia Jain
Stefan K Barta
Seda Tolu
Brian Estrella
Ahmed Sawas
Jennifer K Lue
Mark M Francescone
Barbara Pro
Jennifer E Amengual
Affiliated Authors:
Yun Kyoung Ryu Tiger
Seda Tolu
Brian Estrella
Ahmed Sawas
Mark M Francescone
Barbara Pro
Jennifer E Amengual
Columbia Affiliation:
Subjects:
Aminopterin (MeSH)
Depsipeptides (MeSH)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Lymphoma, T-Cell (MeSH)
Histone Deacetylase Inhibitors (MeSH)
Author Keywords:
chemotherapeutic approaches
lymphoma and hodgkin disease
clinical results
t-cell lymphoma
epigenetics
antifolate
elink
Publication Type:
Article
Unique ID:
10.1080/10428194.2024.2329996
PMID:
38517235
DOI:
10.1080/10428194.2024.2329996
Journal:
Leukemia and Lymphoma
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record

Record Created: